USD
$0.00
(0.00%
)At Close (As of Dec 1, 2025)
$129.44M
Market Cap
3.424
P/E Ratio
0.79
EPS
$6.96
52 Week High
$2.31
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $139M |
| Total Revenue | $197M |
| Cost Of Revenue | $58M |
| Costof Goods And Services Sold | $58M |
| Operating Income | $32M |
| Selling General And Administrative | $107M |
| Research And Development | - |
| Operating Expenses | $107M |
| Investment Income Net | - |
| Net Interest Income | -$11M |
| Interest Income | - |
| Interest Expense | $11M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3.6M |
| Income Before Tax | $1M |
| Income Tax Expense | $970K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $46K |
| Comprehensive Income Net Of Tax | - |
| Ebit | $12M |
| Ebitda | $16M |
| Net Income | $3.2M |
| Field | Value (USD) |
|---|---|
| Total Assets | $122M |
| Total Current Assets | $68M |
| Cash And Cash Equivalents At Carrying Value | $39M |
| Cash And Short Term Investments | $39M |
| Inventory | $15M |
| Current Net Receivables | $7.7M |
| Total Non Current Assets | $54M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $9.4M |
| Intangible Assets Excluding Goodwill | $9.4M |
| Goodwill | $5.8M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $6.2M |
| Other Non Current Assets | - |
| Total Liabilities | $225M |
| Total Current Liabilities | $52M |
| Current Accounts Payable | $5.8M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $6.8M |
| Total Non Current Liabilities | $173M |
| Capital Lease Obligations | $3.4M |
| Long Term Debt | $101M |
| Current Long Term Debt | $6.3M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $111M |
| Other Current Liabilities | $36M |
| Other Non Current Liabilities | $67M |
| Total Shareholder Equity | -$106M |
| Treasury Stock | - |
| Retained Earnings | -$100M |
| Common Stock | $4K |
| Common Stock Shares Outstanding | $34M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $45M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $3.6M |
| Capital Expenditures | $6.4M |
| Change In Receivables | - |
| Change In Inventory | $3.7M |
| Profit Loss | - |
| Cashflow From Investment | -$19M |
| Cashflow From Financing | -$76M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $4.7M |
| Dividend Payout Common Stock | $4.7M |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$5.6M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $46K |
| Field | Value (USD) |
|---|---|
| Gross Profit | $139M |
| Total Revenue | $197M |
| Cost Of Revenue | $58M |
| Costof Goods And Services Sold | $58M |
| Operating Income | $32M |
| Selling General And Administrative | $107M |
| Research And Development | - |
| Operating Expenses | $107M |
| Investment Income Net | - |
| Net Interest Income | -$11M |
| Interest Income | - |
| Interest Expense | $11M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3.6M |
| Income Before Tax | $1M |
| Income Tax Expense | $970K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $46K |
| Comprehensive Income Net Of Tax | - |
| Ebit | $12M |
| Ebitda | $16M |
| Net Income | $3.2M |
Sector: HEALTHCARE
Industry: MEDICAL CARE FACILITIES
Biote Corp (BTMD), headquartered in Irvine, Texas, is a leader in the hormone replacement therapy sector, particularly known for its bioidentical hormone replacement therapy (BHRT) and nutrient optimization solutions designed to enhance patient well-being. With a strong emphasis on personalized medicine and a robust network of trained healthcare providers, the company is dedicated to improving patient outcomes through education and evidence-based practices. Biote's strategic focus on technological advancements and market expansion solidifies its leadership position in the industry, positioning the company for sustained growth in a rapidly evolving healthcare environment.